Citigroup’s Alpha Tau Medical DRTS Stock Holding History

Citigroup’s Portfolio DRTS Stock Details DRTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Buy	1,079 +579	+116%	+$5.26K	﹤0.01%	5204
2026 Q1	$3.54K	Sell	500 -1,000	-67%	-$7.06K	﹤0.01%	5334
2025 Q4	$7.42K	Buy	+1,500	New	+$6.32K	﹤0.01%	5139
2023 Q4	–	Sell	-14,968	Closed	-$56.7K	–	5738
2023 Q3	$56.7K	Sell	14,968 -322,793	-96%	-$1.18M	﹤0.01%	4094
2023 Q2	$1.48M	Buy	337,761 +313,657	+1,301%	+$1.12M	﹤0.01%	2509
2023 Q1	$69.2K	Sell	24,104 -22	-0.1%	-$77	﹤0.01%	4154
2022 Q4	$76.7K	Sell	24,126 -5,592	-19%	-$23.1K	﹤0.01%	4126
2022 Q3	$174K	Buy	+29,718	New	+$262K	﹤0.01%	3833
2022 Q2	–	Sell	-460	Closed	-$5K	–	6324
2022 Q1	$5K	Buy	+460	New	+$5.41K	﹤0.01%	5807

Other funds holding DRTS

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Citigroup's DRTS Position: Q2 2026 in Review

Citigroup increased its Alpha Tau Medical (DRTS) stake by 116% in Q2 2026, buying an estimated $5.26K and bringing the position to 1,079 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5204.

Citigroup first reported a position in DRTS in Q1 2022 and has held it in 9 quarters since. The position peaked at $1.48M in Q2 2023. 74 funds tracked by Wall St. Rank hold DRTS as of Q2 2026.

Citigroup held 1,079 shares of Alpha Tau Medical worth $13.6K as of Q2 2026.
Citigroup bought 579 Alpha Tau Medical shares in Q2 2026, an estimated $5.26K.
Alpha Tau Medical made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5204 holding.
Citigroup first reported a position in Alpha Tau Medical in Q1 2022 and has held it in 9 quarters since.
Citigroup's Alpha Tau Medical position peaked at $1.48M in Q2 2023.
74 funds tracked by Wall St. Rank held Alpha Tau Medical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.